France Begins Reimbursement for Saliva-Based Endometriosis Diagnostic Tests

The experimental Endotest, designed to reduce diagnostic delays, is now covered for eligible women under a limited trial program.

The Endotest, developed by biotech company Ziwig, uses saliva to detect endometriosis through micro-RNA analysis and AI algorithms.
The test, which costs approximately €800 per patient, is being reimbursed by France's Assurance Maladie for up to 25,000 women under specific criteria.
An initial 2,500 patients will participate in a clinical study to evaluate the test's impact on reducing diagnostic surgeries and improving care.
Eligible women are those aged 18–43 with significant symptoms but inconclusive imaging results, according to the Health Ministry's guidelines.
Results from the trial will inform the potential nationwide rollout of the test, aiming to address the average seven-year diagnostic delay for endometriosis.